Leading generics pharmaceutical company
WHO chief on Monday urged for an increase in production of steroid dexamethasone to treat the critically-ill Covid-19 patients. Taj Pharmaceuticals, the well-known Dexamethasone Tablets API Manufacturer in India gives the assurance of high-quality and purity. The stringent quality-control ensure that every batch of the drug brings a consistent standard.
Dexamethasone is a type of corticosteroid medication manufactured by Taj Pharmaceuticals India. It is used in the treatment of many conditions, including COVID-19 respiratory side effects, rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, eye pain following eye surgery, and along with antibiotics in tuberculosis. In adrenocortical insufficiency, it should be used together with a medication that has greater mineralocorticoid effects such as fludrocortisone.[1] In preterm labor, it may be used to improve outcomes in the baby. It may be taken by mouth, as an injection into a muscle, or intravenously. The effects of dexamethasone are frequently seen within a day and last for about three days.
It’s likely you can, at least for some period of time. That is opening new opportunities for testing and treatment. #CoronaVirus #CoronaPrevention #Safety #tajpharmaCorona #CoronaSpread #IndiaFightsCorona #CoronavirusOutbreakindia #CoronavirusPandemic #StaySafeStayHome #IndiaFightsCoronavirus
The WHO said there’s no evidence serological tests can show whether a person has immunity or is no longer at risk of becoming reinfected. The World Health Organization issued a warning Friday about coronavirus testing, saying there’s no evidence serological tests can show whether a person has immunity or is no longer at risk of becoming reinfected. Bacteria & Viruses, coronavirus, COVID-19, Disease Info, Disease Trends, Drug Approvals, Drug News, Health & Disease, Health News, Industry News, Infectious Disease, Medical News, Press Release
ProPublica’s health reporter Caroline Chen explains what the conversation around asymptomatic coronavirus carriers is missing, and what we need to understand if we’re going to beat this nefarious virus together.
The FDA has approved an abbreviated new drug application for hydroxychloroquine sulfate tablets to address ongoing shortages of the drug sparked by its still unproven potential as a COVID-19 treatment. The application, submitted by Accord Healthcare, was approved on April 7. The approved indications are uncomplicated malaria due to Plasmodium falciparum, P. malariae, P. ovale, and P. vivax; chronic discoid lupus erythematosus and systemic lupus erythematosus in adults; and acute and chronic rheumatoid arthritis in adults.
Some politicians and doctors are sparring over whether to use Hydroxychloroquine against the new coronavirus, with many scientists saying the evidence is too thin to recommend it now. The drug Hydroxychloroquine can help tame an overactive immune system. It’s been used since the 1940s to prevent and treat malaria, and to treat rheumatoid arthritis and lupus. It’s sold in generic form and under the brand name Plaquenil in the United States. Doctors also can prescribe it off label for other purposes, as many are doing now for COVID-19.
The first COVID-19 vaccine in China is expected to be ready for clinical trials by the end of April, according to Xu Nanping, China’s vice-minister of science and technology. Inovio Pharmaceuticals plans to begin clinical trials on a coronavirus vaccine in April this year.
A woman takes a swab test for the virus. Credit: ITV News Central The government has been under fire for several days now about the rate of testing for Coronavirus, especially among front-line heath workers.
Clinical trials will test if antibodies against the coronavirus prevent infection, aid survival. Can plasma from recovered COVID-19 patients treat the sick?
